Wednesday, June 10, 2026
🇺🇸 FDA

P1 · Therapeutic area intelligence

Oncology patent intelligence

Anticancer agents, immuno-oncology, ADC, and oncology patent filings — grants, expirations, and assignee activity.

Patents
2,004

Quick answer

2,004 US pharmaceutical patents in our index match Oncology title keywords (A61K/A61P). Cross-link to related drug therapeutic-area hubs and company patent portfolios for full IP context.

  1. US 2016175302

    MASITINIB FOR TREATING GASTRIC CANCER

    AB SCIENCE [FR] · Granted Thu Jun 23 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Jun 18 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. WO 2016096933

    MASITINIB COMBINÉ À UTILISER DANS LE TRAITEMENT DU CANCER DU SEIN

    AB SCIENCE [FR] · Granted Thu Jun 23 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Jun 18 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 9371375

    Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers

    PRECISION BIOLOGICS, INC. · Granted Tue Jun 21 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 16 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 9370521

    Targeting GLI proteins in human cancer by small molecules

    The Regents of the University of California · Granted Tue Jun 21 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 16 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 2016159901

    DIAGNOSIS AND THERAPY OF CANCER INVOLVING CANCER STEM CELLS

    GANYMED PHARMACEUTICALS AG [DE] · Granted Thu Jun 09 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Jun 04 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 9351964

    Methods for treating cancer and non-neoplastic conditions

    PTC THERAPEUTICS, INC. · Granted Tue May 31 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 26 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 9351997

    Method of treating cancer

    Intensity Therapeutics, Inc. · Granted Tue May 31 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 26 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. PH 12016500580

    CONJUGATED ANTIBODIES AGAINST LY75 FOR THE TREATMENT OF CANCER

    OXFORD BIOTHERAPEUTICS LTD [GB] · Granted Mon May 30 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Sun May 25 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 9345718

    Phospholipid ether analogs as cancer-targeting drug vehicles

    CELLECTAR BIOSCIENCES, INC. · Granted Tue May 24 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 19 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 9346867

    Cancer-related glycopeptide epitopes, antibodies and methods of use

    SUMITOMO BAKELITE CO., LTD. · Granted Tue May 24 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 19 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 2016128999

    MASITINIB FOR TREATING HEPATIC CANCER

    AB SCIENCE [FR] · Granted Thu May 12 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed May 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 9334522

    Agents and methods to elicit anti-tumor immune response

    The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Tue May 10 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 05 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 9334306

    Leukemia stem cell targeting ligands and methods of use

    The Regents of the University of California · Granted Tue May 10 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 05 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 9327023

    HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue May 03 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 9326950

    Self-assembling nanoparticles composed of transmembrane peptides and their application for specific intra-tumor delivery of anti-cancer drugs

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue May 03 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 9321820

    Compositions and methods for treating bladder cancer

    The Regents of the University of Colorado · Granted Tue Apr 26 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 21 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 9320774

    Method for reducing radio-resistance of prostate cancer cells and/or treating prostate cancer

    China Medical University · Granted Tue Apr 26 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 21 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 9308206

    Compositions and methods for treating colon cancer

    The Board of Regents of the University of Texas System · Granted Tue Apr 12 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 9303077

    Peptide composition for cancer treatment by inhibiting TRPV6 calcium channel activity

    Soricimed Biopharma Inc. · Granted Tue Apr 05 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 31 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 9283185

    Liposomal curcumin for treatment of cancer

    The Board of Regents of the University of Texas System · Granted Tue Mar 15 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 10 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 9266960

    Anti-epidermal growth factor receptor variant III chimeric antigen receptors and use of same for the treatment of cancer

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Feb 23 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 18 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 9266813

    Stilbenoid compound as inhibitor for squamous carcinoma and hepatoma and uses thereof

    China Medical University · Granted Tue Feb 23 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 18 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 9266901

    Compositions and methods for treating cancer

    The Regents of the University of California · Granted Tue Feb 23 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 18 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 9265804

    Compositions and methods for treatment of cancer using bacteria

    Decoy Biosystems, Inc. · Granted Tue Feb 23 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 18 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 9255155

    Antibodies specific for urokinase-type plasminogen activator and methods of treating cancer

    The Regents of the University of California · Granted Tue Feb 09 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 04 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 9241998

    Methods and compositions for treatment of cancer using oncolytic RSV activity

    The Board of Regents of the University of Texas System · Granted Tue Jan 26 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 21 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 9243068

    Combination of SEMA-4D inhibitors and immunomodulators to inhibit tumors and metastases

    VACCINEX, INC. · Granted Tue Jan 26 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 21 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 9242000

    Micro-RNAs and micro-RNA inhibitors to modulate blood vessel growth, patterning, tumor growth and malignant disease and method for making and using them

    The Regents of the University of California · Granted Tue Jan 26 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 21 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 9238838

    Microrna patterns for the diagnosis, prognosis and treatment of melanoma

    TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD. · Granted Tue Jan 19 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 14 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 9238069

    Method of sensitizing cancer cells to the cytotoxic effects of death receptor ligands in cancer treatment

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Jan 19 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 14 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 9233121

    Compositions and methods for the treatment of cancer

    BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted Tue Jan 12 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 9220772

    Anti-tumor antigen antibodies and methods of use

    The Regents of the University of California · Granted Tue Dec 29 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 24 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 9222086

    Compositions and methods for silencing genes expressed in cancer

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Dec 29 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 24 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 9217007

    Platinum anticancer agents

    The Regents of the University of California · Granted Tue Dec 22 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 17 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 9205131

    Use of IL-17D for the treatment and prevention of cancers

    The Regents of the University of California · Granted Tue Dec 08 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 9205091

    Diazeniumdiolated compounds, pharmaceutical compositions, and method of treating cancer

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Dec 08 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 9206245

    Immunogenic peptides and methods of use for treating and preventing cancer

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Dec 08 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 9198893

    Combination antitumor therapy

    Galera Labs, LLC · Granted Tue Dec 01 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 26 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 9169326

    Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers

    PRECISION BIOLOGICS, INC. · Granted Tue Oct 27 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 22 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 9169313

    Method of treatment of cancers characterized by ligand-dependent activating mutations in FGFR2 with FGFR1 ECD proteins

    Five Prime Therapeutics, Inc. · Granted Tue Oct 27 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 22 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 9168266

    Hybrid diazeniumdiolated compounds, pharmaceutical compositions, and method of treating cancer

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Oct 27 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 22 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 9168291

    β-mannosylceramide and stimulation of NKT cell anti-tumor immunity

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Oct 27 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 22 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 9163236

    Pharmaceutical composition comprising NANOG SHRNA, and method of using NANOG SHRNA to treat cancer

    The United States of America as Represented by the Secretary, Dept. of Health and Human Services · Granted Tue Oct 20 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 15 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 9163085

    Anti-OX40 antibodies and methods of treating cancer

    The Board of Regents of the University of Texas System · Granted Tue Oct 20 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 15 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 9156853

    AKT inhibitor compounds for treatment of cancer

    ALMAC DISCOVERY LIMITED · Granted Tue Oct 13 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 08 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 9149489

    Inhibitors of glycolysis useful in the treatment of brain tumors

    The Board of Regents of the University of Texas System · Granted Tue Oct 06 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 01 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 9150926

    Diagnosis and treatment of adrenocortical tumors using human microRNA-483

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Oct 06 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 01 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 9139634

    Interferon-antibody fusion proteins demonstrating potent apoptotic and anti-tumor activities

    The Regents of the University of California · Granted Tue Sep 22 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 17 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many Oncology patents are indexed?

2,004 patents match our Oncology classifier (title keywords in USPTO records).

Is this legal or medical advice?

No — patent intelligence is for professional reference. Verify expiration and FTO with qualified patent counsel and primary USPTO records.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.